Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 4;7(4):fcaf243.
doi: 10.1093/braincomms/fcaf243. eCollection 2025.

Deep learning to predict progression independent of relapse activity at a first demyelinating event

Affiliations

Deep learning to predict progression independent of relapse activity at a first demyelinating event

Llucia Coll et al. Brain Commun. .

Abstract

Progression independent of relapse activity is the main cause of irreversible disability in multiple sclerosis and is strongly associated with older age at symptom onset. Early and accurate prediction, at symptom onset, of which patients are at highest risk of progression independent of relapses, is an unmet need. This study aimed to develop a deep learning survival model using only routine MRI acquired at the first demyelinating attack to predict the risk of progression independent of relapses, and assess its ability to improve classical age-adjusted predictions. We analysed a prospective cohort of patients under 50, clinically assessed within three months of symptom onset, with available MRI (T1- and T2-Fluid-Attenuated Inversion Recovery sequences). An independent early multiple sclerosis cohort (≤1 year from symptom onset) from the Multiple Sclerosis Partners Advancing Technology and Health Solutions database (N = 32) was used for external validation. Patients were assessed for progression independent of relapse activity, defined as a 6-month confirmed increase in the Expanded Disability Status Scale without relapses. Our deep learning model used EfficientNet to estimate the cumulative probability of progression independent of relapses at 1-year intervals. We employed 5-fold cross-validation for model training and testing, assessing performance with the time-dependent concordance index. We also investigated the optimal cumulative probability threshold for binary risk stratification. The model's ability to improve a classical Cox regression model was evaluated. Additionally, we identified brain regions most relevant to deep learning-based progression independent of relapse activity predictions using an interpretability algorithm. A total of 259 patients were evaluated, 58 (22%) of whom experienced at least one event of progression independent of relapse activity over a median follow-up of 4.2 years. The deep learning model demonstrated high performance (time-dependent concordance index = 0.72) with an accuracy of 78% in the original cohort and 72% in the external cohort for predicting the risk of progression independent of relapse activity. Incorporating the deep learning-derived cumulative probability of progression independent of relapses significantly improved an age-adjusted Cox regression model, raising Harrell's C index from 0.62 to 0.74. Interpretability revealed the frontoparietal cortex as a key region in predicting progression independent of relapse activity. In conclusion, our deep learning survival model, based on routine MRI at the first demyelinating attack, can accurately identify patients at high risk of progression independent of relapses and may serve as a valuable tool in clinical practice.

Keywords: brain MRI; deep learning; multiple sclerosis; predictive model; progression independent of relapse activity.

PubMed Disclaimer

Conflict of interest statement

L.C., F.A.-S., J.C., A.Z., I.G., L.M., M.A. and A.O. have nothing to disclose. D.P. has received a research contract with Biogen Idec, and a grant from Instituto Salud Carlos III (PI18/00823). A.C.-C. has received a grant from Instituto de Salud Carlos III, Spain; JR19/00007. G.A. has received compensation for consulting services, participation in advisory boards or speaking honoraria from Merck, Roche and Horizon Therapeutics; and travel support for scientific meetings from Novartis, Roche, and ECTRIMS. G.A. is editor for Europe of the Multiple Sclerosis Journal—Experimental, Translational and Clinical; a member of the executive committee of the International Women in Multiple Sclerosis (iWiMS) network, and a member of the European Biomarkers in MS (BioMS-eu) consortium steering committee. She is a recipient of grants PI19/01590 and PI22/01570, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España. Á.V.-J. has engaged in consulting and/or participated as speaker in events organized by Roche, Novartis, Merck and Sanofi. M.C. has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis and Novartis. B.R.-A. has received honoraria for consulting services from Wellspect. C.N. has received funding for travel from Biogen Idec and F. Hoffmann-La Roche, Ltd. and speaker honoraria from Novartis. C.A. has received speaking honoraria from Novartis, Biogen and Stendhal. J.R. has received speaking honoraria and personal compensation for participating on Advisory Boards from Biogen-Idec, Genzyme, Merck-Serono, Mylan, Novartis, Roche, Teva and Sanofi-Aventis. J.S.-G. serves as co-Editor for Europe on the editorial board of Multiple Sclerosis Journal and as Editor-in-Chief in Revista de Neurología, receives research support from Fondo de Investigaciones Sanitarias (19/950) and has served as a consultant/speaker for Biogen, Celgene/Bristol Meyers Squibb, Genzyme, Novartis and Merck. X.M. has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Abbvie, Actelion, Alexion, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS. A.R. serves/ed on scientific advisory boards for Novartis, Sanofi-Genzyme, Synthetic MR, Roche, Biogen, Bayer and OLEA Medical; has received speaker honoraria from Bayer, Sanofi Genzyme, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, and Biogen; and is CMO and co-founder of TensorMedical. M.T. has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis and Teva Pharmaceuticals. M.T. is former co-editor of Multiple Sclerosis Journal. X.L. is currently being supported by the ICREA Academia Program. He has also received support from the PID2020-114769RBI00 and the PID2023-146187OB-I00 projects funded by the Ministerio de Ciencia, Innovación y Universidades. C.T. is currently being funded by a Miguel Servet contract, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (CP23/00117). She has also received a 2020 Junior Leader La Caixa Fellowship (fellowship code: LCF/BQ/PI20/11760008), awarded by ‘la Caixa’ Foundation (ID 100010434), a 2021 Merck’s Award for the Investigation in MS, awarded by Fundación Merck Salud (Spain), 2021 and 2024 Research Grants (PI21/01860 and PI24/01277) awarded by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación de España, and a FORTALECE research grant (FORT23/00034) also by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación de España. In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She is a member of the Editorial Board of Neurology Journal and Multiple Sclerosis Journal. She has also received honoraria from Roche, Novartis, Merck, Sanofi, Johnson and Johnson, and Bristol Myers Squibb, and is a steering committee member of the O’HAND trial and of the Consensus group on Follow-on DMTs.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Study design. DL model. (A) Overview of the proposed pipeline for the prediction of survival probabilities and their evaluation. The T2-FLAIR and T1-w 2D slices are used as input to the pre-trained EfficientNet-b0, whose extracted features are grouped in the discrete predictor to predict the discrete survivor function S^(t), that is, the time-discrete interval-specific survival probabilities, i.e. the probabilities of not reaching PIRA. The predictor block consists of a fully connected layer, which outputs an 11-dimension vector, one for each time interval, followed by a sigmoid activation function, which outputs 11 (interval-specific) survival probabilities. These survival probabilities conform the survivor function, S^(t), representing the probability of not reaching PIRA at each discrete time t (at each time interval). Then, the cumulative probability of having had the PIRA event by time t, i.e. the cumulative distribution function  F^(t), is obtained as 1S^(t). These interval-specific cumulative probabilities of reaching the event PIRA are then used to find the best threshold to identify, which patients will finally develop the event. Also, these interval-specific probabilities of PIRA are added as covariates in a Cox Proportional Hazards model predicting time to first PIRA (see the Material and methods section for more details). (B) EfficientNet-b0 architecture and the main layers forming the convolutional and residual blocks. Conforming the MBConv block there were depth-wise convolutional layers, which expand features instead of reducing them. After that, SE blocks were used to improve the quality of representations by explicitly modelling the inter-dependencies between the channels. Additionally, in between these two blocks a Swish activation was used, defined as f(x) = x · Sigmoid(x), that tends to work better than ReLU on deeper models. B, output feature maps; Conv, convolutional layer; DL, deep learning; FC, fully connected; GAP, global adaptive pooling; k, kernel size; M, input feature maps; MBConv, mobile inverted bottleneck; PIRA, progression independent of relapse activity; r, reduction ration of SE; s, stride; SE, squeeze-and-excitation; T1-w, T1-weighted image; T2-FLAIR, T2-weighted fluid-attenuated inversion recovery.
Figure 2
Figure 2
Patient flowchart. EDSS, expanded disability status scale; IC, informed consent; PIRA, progression independent of relapse activity.
Figure 3
Figure 3
DL-based predictions in the original cohort. (A) Overlay of Kaplan–Meier curve (grey) and DL-based survival predictions of PIRA (pink line) in the original cohort. The darker pink ribbon represents the 95% CI of the estimation, whereas the lighter pink one represents the 95% reference range, i.e. the DL-predicted PIRA survival probabilities in the population, from the 2.5th to the 97.5th percentiles. As observed, the DL-based predictions accurately mirrored the Kaplan–Meier curve, especially from symptom onset until the 8th year of follow-up. The mean time-dependent concordance index (ctd) across folds was 0.72 (range 0.68 to 0.78) and the mean IBS was 0.1 (SD 0.04). (B). DL-based predicted probabilities of PIRA at each time interval. Here, each dot in the graph represents the predicted probability of developing PIRA. Patients who developed PIRA during the follow-up had, on average, greater DL-predicted risk of developing PIRA at all time points: Mann–Whitney U-test (for comparison of medians): Interval 1: z (test statistic, large-sample normal [Z] approximation of the U statistic) = −4.501, P = 6.8·10−6; Interval 2: z = −4.465, P = 8·10−6; Interval 3: z = −4.168, P = 3.1·10−5; Interval 4: z = −3.940, P = 8.2·10−5; Interval 5: z = −3.977, P = 7·10−5; Interval 6: z = −3.896, P = 9.8·10−5; Interval 7: z = −3.860, P = 0.00011; Interval 8: z = −3.534, P = 0.00041; Interval 9: z = −3.373, P = 0.00075; Interval 10: z = −3.500, P = 0.00047; Interval 11: z = −3.400, P = 0.00064. Sample size for all comparisons: N = 259. DL, deep learning; IBS, integrated Brier score; SD, standard deviation; PIRA, progression independent of relapse activity.
Figure 4
Figure 4
Assessment of DL model performance and interpretability. (A) Comparison of ROC curves for the different interval-specific cumulative probability of a first PIRA event: the AUC for the first interval-specific probability is the greatest, although the difference with the rest of the curves did not reach statistical significance according to a χ2 test, correcting for multiple comparisons (Šidák correction): χ2 statistic (10 degrees of freedom) = 17.32, P = 0.0676. Sample size: N = 259. (B) Coefficient plot showing the independent contribution of age and lesion load at first attack plus the DL-based cumulative probabilities of PIRA, estimated at the first time interval, to predict PIRA through a Cox PH model (and Wald tests to assess individual covariate effects): age at first attack (in decades): aHR = 1.482 (1.041; 2.111), z (test statistic) = 2.18, P = 0.029; number of brain T2 lesions at first attack: aHR = 1.093 (1.014; 1.179), z = 2.31, P = 0.021; DL-based cumulative probabilities of PIRA: aHR = 1.449 (1.306; 1.607), z = 7.01, P < 0.001. Sample size for all analyses: N = 259. (C) Population-average maps of SHAP values, i.e. relevance maps (top row) and the most relevant areas for predicting PIRA (bottom row). Most relevant regions for PIRA prediction were the frontal and parietal cortex, lateral ventricles, periventricular, frontal and parietal WM. Cortical areas had a more negative relevance, lateral ventricles a more positive one, while a similar relevance value was observed in periventricular WM. Sample size for all analyses: N = 259. 95% CI, 95% confidence interval; aHR, adjusted hazard ratio; AUC, area under the ROC curve; Cox PH, Cox proportional hazards; DL, deep learning; PIRA, progression independent of relapse activity; ROC, receiver operating characteristic; WM, white matter.
Figure 5
Figure 5
DL-based predictions in the validation cohort. (A) Overlay of Kaplan–Meier curve (grey) and DL-based survival predictions of PIRA (orange line) in the validation cohort. The darker orange ribbon represents the 95% CI of the estimation, whereas the lighter orange one represents the 95% reference range, i.e. the DL-predicted PIRA survival probabilities in the population, from the 2.5th to the 97.5th percentiles. In the validation cohort, the DL-estimated survival probabilities of PIRA mirrored those of the Kaplan–Meier curve until the 5-year follow-up, when the two curves started to separate. (B) DL-based predicted probabilities of PIRA at each time interval. Here, each dot in the graph represents the predicted probability of developing PIRA. As in the original cohort, patients who developed PIRA during the follow-up had, on average, greater DL-predicted risk of developing PIRA at all time points. However, these differences did not reach statistical significance: Mann–Whitney U-test (for comparison of medians): Interval 1: z (test statistic, large-sample normal [Z] approximation of the U statistic) = −0.189, P = 0.87; Interval 2: z = −0.519, P = 0.63; Interval 3: z = −0.377, P = 0.73; Interval 4: z = −0.189, P = 0.87; Interval 5: z = −0.094, P = 0.95; Interval 6: z = −0.141, P = 0.91. Sample size for all comparisons: N = 32. DL, deep learning; PIRA, progression independent of relapse activity.

References

    1. Kappos L, Butzkueven H, Wiendl H, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2018;24(7):963–973. - PMC - PubMed
    1. Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147–3161. - PMC - PubMed
    1. Portaccio E, Bellinvia A, Fonderico M, et al. Progression is independent of relapse activity in early multiple sclerosis: A real-life cohort study. Brain. 2022;145(8):2796–2805. - PubMed
    1. Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 2023;80(2):151–160. - PMC - PubMed
    1. Collorone S, Coll L, Lorenzi M, et al. Artificial intelligence applied to MRI data to tackle key challenges in multiple sclerosis. Mult Scler. 2024;30(7):767–784. - PubMed

LinkOut - more resources